Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01104805 · ClinicalTrials.gov registry record · NA

Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders

A NA study of Substance Abuse, sponsored by New York State Psychiatric Institute.

Completed
Registry status
NA
Development phase
507
Enrollment target
10
Study locations

NCT01104805: Completed NA study of Substance Abuse, sponsored by New York State Psychiatric Institute.

NCT01104805 is a NA study of Substance Abuse that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 507 participants, below the 5,251-participant average among 58 other Substance Abuse trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01104805, a NA study of Substance Abuse, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
NA
Development phase
507 participants
Enrollment target
10
Study locations

Study Summary

The main objective of this study is to evaluate the effectiveness of including an interactive, web-based version of the Community Reinforcement Approach (CRA), called the Therapeutic Education System (TES), as part of community-based, outpatient substance abuse treatment.

Primary Outcome

Compared to patients assigned to Treatment as Usual (TAU), patients assigned to modified TAU plus the Therapeutic Education System (Modified TAU + TES) will have: 1. reduced substance use (measured by a combination of self-report confirmed by urine toxicology) and 2. better retention in treatment at their community-based treatment programs.

Conditions Studied

Interventions

  • BEHAVIORAL Treatment-as-Usual (TAU)
  • BEHAVIORAL Therapeutic Education System (TES)

Study Locations (10)

Connecticut

  • MCCA: Midwestern CT Council on Alcoholism - Danbury

Florida

  • The Center for Drug Free Living - Orlando

Hawaii

  • Hina Mauka - Waipahu

Indiana

  • Midtown Community Mental Health Center - Indianapolis

Maryland

  • HARBEL Prevention and Recovery Center - Baltimore

Massachusetts

  • Stanley Street Treatment and Resources (SSTAR) - Fall River

New York

  • Project Outreach - West Hempstead

Oregon

  • Willamette Family, Inc. - Eugene

Trial Details

FieldValue
Enrollment Target 507 participants
Start Date 2010-04
Est. Completion 2012-09
Phase NA

What the finished NCT01104805 record still lists

NCT01104805 is an interventional study that assigns participants to a tested intervention. The registered 507 participants enrollment target is mid-sized for trials with a published cap, below the 5,251-participant average among 58 other Substance Abuse trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Substance Abuse appearing as the primary indexed condition, and to 2 interventions - of which Treatment-as-Usual (TAU) is the first listed.

NCT01104805 lists 10 locations in 10 states (Connecticut, Florida, Hawaii).

Frequently Asked Questions

What is clinical trial NCT01104805 about?

NCT01104805 is a clinical study titled "Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders". The main objective of this study is to evaluate the effectiveness of including an interactive, web-based version of the Community Reinforcement Approach (CRA), called the Therapeutic Education System (TES), as part of community-based, outpatient substance abuse treatment.

What is the current status of trial NCT01104805?

This trial is currently completed. It is a NA study. The enrollment target is 507 participants. The study started on 2010-04. Estimated completion is 2012-09.

What conditions does trial NCT01104805 study?

This clinical trial studies the following conditions: Substance Abuse.

What interventions are being tested in trial NCT01104805?

The interventions under investigation include: Treatment-as-Usual (TAU) (BEHAVIORAL), Therapeutic Education System (TES) (BEHAVIORAL).

Who is sponsoring clinical trial NCT01104805?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01104805 being conducted?

This trial has 10 study locations across Connecticut, Florida, Hawaii, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01104805's enrollment target sits among peer trials

507 12th of 58 higher than 47 of 58 other Substance Abuse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06164717 · 507 participants · NA

    Behavioral and Neural Characteristics of Adaptive Speech Motor Control

  • NCT02115295 · 508 participants · Phase 2

    Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

  • NCT04692675 · 508 participants · NA

    Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

  • NCT07391657 · 508 participants · Phase 3

    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01104805, the US trial registry maintained by the National Library of Medicine. NCT01104805 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.